Medical/Pharmaceuticals
Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings DUBLIN, Aug. 18, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today ann...
2025-08-18 21:30
3077
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
* This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...
2025-08-18 21:00
3452
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
* Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion * Research and development expenses was approximately RMB611.5 million * Loss for the period was RMB145.2 million; adjusted loss for the period[1] ...
2025-08-18 18:29
3278
India's leading healthcare network Manipal Hospitals welcomes India's leading cancer specialist Dr. Surender Kumar Dabas to strengthen robotic cancer care in Delhi NCR
NEW DELHI, Aug. 18, 2025 /PRNewswire/ -- Manipal Hospitals, one of India's
leading and globally recognized healthcare institutions, welcomes one ofIndia's
most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas
2025-08-18 18:23
2193
Next Generation Refractive Surgery to LASIK and SMILE Now Available for Clinical Review
Pioneer surgeon Dr Natasha Lim is among the first in Singapore to offer Smooth Incision Lenticular Keratomileusis (SILK) procedure in their clinics. SINGAPORE, Aug. 18, 2025 /PRNewswire/ -- Dr. Natasha Lim, an internationally renowned surgeon in Ophthalmology, has introduced an alternative to est...
2025-08-18 11:00
2506
New support group to provide social and community support for neurofibromatosis patients
Co-founded by individuals living with this rare genetic condition, the Neurofibromatosis Society Singapore seeks to close gaps in mental and emotional care SINGAPORE, Aug. 18, 2025 /PRNewswire/ -- A new patient-led support group, the Neurofibromatosis Society (NFS)Singapore, has been recently re...
2025-08-18 09:00
2283
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has be...
2025-08-15 09:35
2835
TraceLink Accelerates Supply Chain Transformation with New OPUS Platform Capabilities for an AI-Powered Future
BOSTON, Aug. 14, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with itsOrchestration Platfor...
2025-08-14 22:00
2481
Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma
NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LB...
2025-08-14 17:38
4220
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Adminis...
2025-08-14 12:02
3139
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
* Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) * NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irr...
2025-08-14 08:00
2926
The Rainwater Charitable Foundation, Aging Mind Foundation, Alzheimer's Association, and CurePSP Join Forces to Award $2.5 Million in Neurodegenerative Disease Research Grants from 2025 Tauopathy Challenge Workshop
Established in 2023, the Tauopathy Challenge Workshop aims to bridge the gap in funding of novel neurodegenerative research for primary tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs). FORT WORTH, Texas, Aug. 13, 2...
2025-08-13 20:00
2388
New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team
MINNEAPOLIS, Aug. 13, 2025 /PRNewswire/ -- A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in...
2025-08-13 19:30
2088
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndr...
2025-08-13 17:57
2850
Avive Health to host Queensland's first Empax clinic in landmark mental health partnership with Emyria
BRISBANE, Australia, Aug. 13, 2025 /PRNewswire/ -- Avive Health ("Avive"), an Australian-owned private mental health provider, has announced a major national partnership with Emyria Limited (ASX: EMD), marking a significant milestone in the evolution of evidence-based, reimbursable mental heal...
2025-08-13 15:40
2934
Prince Court Medical Centre Strengthens Malaysia's Position as a Global Healthcare Destination with First Kelly Procedure
KUALA LUMPUR, Malaysia, Aug. 13, 2025 /PRNewswire/ -- Prince Court Medical
Centre has placedMalaysia firmly on the global medical tourism map by
successfully performing the country's first Kelly procedure, an advanced
reconstructive surgery for rare congenital urological conditions.
2025-08-13 15:16
2632
KBP's Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration
SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company ") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr....
2025-08-13 09:44
5812
Manipal Hospitals Kolkata completes 50 successful TAVR cases
KOLKATA, India, Aug. 12, 2025 /PRNewswire/ -- Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital),Kolkata is thrilled to announce the completion of50 successful Transcatheter Aortic Valve Replacement (TAVR) cases, establishing the facility as a regional market leader in struc...
2025-08-12 17:29
2041
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading technologies,...
2025-08-12 17:00
3383
Intas & Accord signs Agreement to acquire Prothya Biosolutions
AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based...
2025-08-11 21:41
4006
Week's Top Stories
Most Reposted
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
14270
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12958
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
12102
